leukemia

Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...

...

03/16/2020

Journal of Clinical Pathways

Feature

Current State of Myelodysplastic Syndromes: Standard Treatment Practices and Therapeutic Advances

08/19/2019

Elizabeth A. Griffiths , MD;

Mark G. Faber , DO;

Swapna Thota , MD;

Abstract: Patients with myelodysplastic syndromes (MDS) collectively have a high symptom burden and are also at risk of death from complications of cytopenias and acute myeloid leukemia. The goals of therapy for...

...

08/19/2019

Journal of Clinical Pathways

From the Field

Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program

06/08/2018

Jonathan Gerber , MD;

Zainab Shahi ;

Saad Z. Usmani , MD, FACP;

Michael R. Grunwald , MD;

Jigar Trivedi , MS, PharmD, BCOP;

Tammy Cogdill , MSN, ANP-BC, OCN;

Nilanjan Ghosh , MD, PhD;

Belinda R. Avalos , MD;

Dragos Plesca , PharmD, PhD, BCOP;

Manisha Bhutani , MD, PhD;

To read the full article, click here.

To...

06/08/2018

Journal of Clinical Pathways

Research in Review

Androgen Therapy May Improve Survival in Elderly Patients With Leukemia

10/24/2016

JCP Editors

Maintenance therapy with norethandrolone may improve survival in elderly patients with acute myeloid leukemia (AML) without increasing toxicity, according to a study published in the Journal of Clinical Oncology....

...

10/24/2016

Journal of Clinical Pathways

Research in Review

Novel, Low-Cost Method for Examining Leukemia Cells Developed

10/19/2016

JCP Editors

A group of Swedish researchers may have found a cost-efficient way of examining individual leukemia cells, which could transform treatment strategies and make care more personalized, according to a study published in...

A...

10/19/2016

Journal of Clinical Pathways

Research in Review

Out-of-Pocket Costs May Delay TKI Initiation in Patients With CML

10/10/2016

JCP Editors

The significant out-of-pocket costs cancer patients face before Medicare Insurance drug benefits kick in may delay initiation of tyrosine-kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML), according...

The...

10/10/2016

Journal of Clinical Pathways

Quiz

Friday Quiz ‚Äì Week of June 13-19

06/16/2016

JCP Editors

Monotherapy with which of the following drugs was found to improve response in patients with chronic lymphocytic leukemia after relapsing or becoming refractory to ibrutinib or...

...

06/16/2016

Journal of Clinical Pathways

Venetoclax Response in Patients With R/R CLL

06/15/2016

JCP Editors

Patients with chronic lymphocytic leukemia (CLL) who are relapsed or refractory (R/R) to ibrutinib or idelalisib may benefit from venetoclax monotherapy, according to a study presented at the 2016 American Society of...

...

06/15/2016

Journal of Clinical Pathways